Thermo Fisher Scientific Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹487

Market cap₹1.8L Cr

P/E24.6

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

3 of 4 strong

RevenueSlow growth

MarginMargins slightly up

CapexCapex planned

Order bookOrder book rising

The short version

- Full-year 2026 revenue guidance raised to $47.3 billion - $48.1 billion, with 3% to 4% organic growth expected. - 2026 full-year adjusted EPS guidance raised to $24.64–$25.12, representing 8% to 10% adjusted EPS growth.

From Thermo Fisher Scientific Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth

Full-year 2026 revenue guidance raised to $47.3 billion - $48.1 billion, with 3% to 4% organic growth expected.
Midpoint organic growth slightly above 3%, including a $900 million revenue contribution from Clario acquisition.
Second quarter organic revenue growth guidance around 3%, with Q2 adjusted EPS expected $0.25-$0.30 higher than Q1.
China currently at low single-digit decline; no meaningful growth assumed for 2026 but potential upside if conditions improve.
Pharma and biotech businesses, especially bioproduction and clinical research, expected to continue strong growth and share gains.
Analytical Instruments segment faces muted demand but innovation pipeline and easier comparisons suggest normalized growth ahead.

2 more points management made on revenue & sales performance

Profitability & Margins

2026 full-year adjusted EPS guidance raised to $24.64–$25.12, representing 8% to 10% adjusted EPS growth.
Organic revenue growth guidance remains 3% to 4%, with midpoint slightly above 3%.
Guidance includes a $900 million revenue increase and $0.32 EPS contribution from Clario acquisition.
Adjusted operating margin expansion expected at 70 basis points for the year.
Q2 organic revenue growth anticipated around 3%, with adjusted EPS $0.25 to $0.30 higher than Q1.
Strong operational performance and productivity gains projected to continue offsetting inflation and mix challenges.

2 more points management made on profitability & margins

See what Thermo Fisher Scientific Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Completed acquisition of Clario in late March, enhancing digital endpoint data solutions and clinical research capabilities.
Strategic collaboration with NVIDIA to commercialize AI-enhanced workflow solutions for scientific instrumentation.
Collaboration with SHL Medical to strengthen U.S. sterile fill-finish and device assembly capabilities using the newly acquired Ridgefield, NJ Sterile fill-finish site.
Opened new Cryo-EM Drug Discovery Center in San Francisco to enhance drug development through Cryo-EM technologies.
Integration progressing smoothly for filtration and separation business acquired from Solventum, driving growth.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

The company’s guidance includes approximately $660 million of net interest expense for the year, which now includes financing for the Clario acquisition.
No mention of new or planned fundraising through equity in this earnings call excerpt.
The firm continues disciplined capital deployment via strategic M&A (e.g., acquisition of Clario and filtration/separation business from Solventum) and returning capital to shareholders (completed $3 billion share buybacks in January and plans approximately $700 million in dividends for the year).

2 more points management made on fundraising & capital structure

See what Thermo Fisher Scientific Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising

The clinical research business demonstrated strong growth in both revenue and authorizations, indicating a robust current order book and pipeline.
There is a "very strong pipeline" of authorizations, referring to work currently underway but not yet in the decision phase, which has moved positively.
The company is seeing continued share gain momentum in clinical research, supported by improving biotech funding.
Early feedback on the recent Clario acquisition is very positive, with customers showing excitement about its technology, suggesting a promising future order pipeline.

2 more points management made on order book & pipeline

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Thermo Fisher Scientific Inc. Q2 FY26 results?

What is Thermo Fisher Scientific Inc. share price analysis?

Thermo Fisher Scientific Inc. currently shows a neutral. The stock trades at a P/E of 24.6 with a market cap of $181,061. Investors should review the full earnings analysis for detailed insights.

Is Thermo Fisher Scientific Inc. planning capital expenditure?

- Completed acquisition of Clario in late March, enhancing digital endpoint data solutions and clinical research capabilities. - Strategic collaboration with NVIDIA to commercialize AI-enhanced workflow solutions for scientific instrumentation. - Collaboration with SHL Medical to strengthen U.S.

Keep Thermo Fisher Scientific Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.